Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to ease Post-Surgery pain without opioids

NCT ID NCT06215859

Symptom relief Sponsor: Viatris Specialty LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called MR-107A-02 for treating acute pain after hernia repair surgery. About 579 adults took part, comparing the drug to a placebo and to tramadol, a standard painkiller. The goal was to see if MR-107A-02 reduces pain intensity and the need for extra opioid rescue medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MR-107A-02 (a pain-relief drug)
What this could lead to
If it works, this could offer a new option for managing pain after hernia surgery, possibly reducing the need for opioid rescue medication.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove more effective than existing treatments like tramadol, and all pain drugs carry side effects such as nausea or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

579 people

The number who actually took part.

Started

Dec 2023

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: 1\. Requirement for unilateral open inguinal herniorrhaphy with mesh under general anesthesia. 3\. Has an American Society of Anesthesiologists Physical Status of I, II, or III. 4\. Pain Intensity (PI) using NRS-R ≥4 at any given timepoint during the 5 hours following end of surgery in the eligibility assessment as well as in the baseline assessment (NRS-R and NRS-A) immediately pre-dosing. 5\. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following end of surgery. 6\. Able to understand and complete the study requirements (including literacy, to enable diary and questionnaire completion), provide written informed consent, and agree to abide by the study protocol and its restrictions. Main Exclusion Criteria: 1. Previously dosed with this formulation of MR 107A 02. 2. Had any prior inguinal hernia repair in the past 24 months. 3. Has a planned concurrent surgical procedure (e.g., bilateral herniorrhaphy). 4. Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain that is not strictly related to the herniorrhaphy, and which may confound the postoperative assessments. 5. Known hypersensitivity to aspirin, NSAIDs, or other medication used in the study. 6. Body mass index (BMI) \>40 kg/m2 at screening. 7. Body weight of \<43 kg (105.8 lbs) at screening. 8. History of GI bleeding or peptic ulcer disease. 9. Known active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis. 10. A history of bleeding disorders that may affect coagulation. 11. Subjects with prior stroke or transient ischemic attack in the past 12 months prior to screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain Pain Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain Pain Post operative pain

Contacts and locations

Locations

  • Investigator site 201

    Salt Lake City, Utah, 84107, United States

  • Investigator site 202

    Anaheim, California, 92801, United States

  • Investigator site 203

    San Antonio, Texas, 78240, United States

  • Investigator site 204

    Houston, Texas, 77008, United States

  • Investigator site 205

    Wichita, Kansas, 67214, United States

  • Investigator site 206

    Tampa, Florida, 33613, United States

  • Investigator site 207

    Atlanta, Georgia, 30331, United States

  • Investigator site 208

    Riverside, California, 92501, United States

  • Investigator site 210

    Sheffield, Alabama, 35660, United States

  • Investigator site 211

    Miami, Florida, 33014, United States

  • Investigator site 212

    Bellaire, Texas, 77401, United States

  • Investigator site 213

    Phoenix, Arizona, 85053, United States

  • Investigator site 214

    San Antonio, Texas, 78258, United States

  • Investigator site 215

    Carrollton, Texas, 75006, United States

  • Investigator site 216

    McAllen, Texas, 78501, United States

  • Investigator site 219

    San Antonio, Texas, 78229, United States

  • Investigator site 222

    Bakersfield, California, 93301, United States

  • Investigator site 224

    Eau Claire, Wisconsin, 54701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.